Mechanism of Maxiong Powder in inhibiting Epac1-Piezo2 signaling pathway in medial habenular nucleus-interpeduncular nucleus of rats with neuropathic pain.
10.19540/j.cnki.cjcmm.20250123.401
- Author:
Xin-Yuan WANG
1
;
Zhi CHEN
1
;
Ying LIU
1
;
Jian SUN
1
;
Ru-Jie LI
1
;
Zhi-Guo WANG
1
;
Mei-Yu ZHANG
1
Author Information
1. Beijing Key Laboratory of Research of Chinese Medicine on Prevention and Treatment for Major Diseases,Experimental Research Center, China Academy of Chinese Medical Sciences Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
Epac1-Piezo2;
Maxiong Powder;
glutamate;
interpeduncular nucleus;
medial habenular nucleus;
neuropathic pain
- MeSH:
Animals;
Neuralgia/genetics*;
Rats;
Signal Transduction/drug effects*;
Male;
Rats, Sprague-Dawley;
Guanine Nucleotide Exchange Factors/genetics*;
Drugs, Chinese Herbal/administration & dosage*;
Habenula/drug effects*;
Ion Channels/genetics*;
Humans
- From:
China Journal of Chinese Materia Medica
2025;50(10):2719-2729
- CountryChina
- Language:Chinese
-
Abstract:
Central sensitization(CS) is an important factor in inducing neuropathic pain(NPP), and the association between signal transduction protein 1(Epac1) and piezoelectric type mechanosensitive ion channel component 2(Piezo2) is a new and significant pathway for initiating CS. This study whether the central analgesic effect of Maxiong Powder is achieved through the synchronized regulation of the Epac1-Piezo2 signaling pathway in the medial habenular nucleus(MHb) and interpeduncular nucleus(IPN) of the brain. Dynamic in vivo microdialysis, combined with high-performance liquid chromatography-fluorescence detection(HPLC-RFC), behavioral assessments, immunohistochemistry, Western blot, and quantitative reverse transcription PCR, were employed in rats with partial sciatic nerve injury(SNI) to investigate the distribution and expression of Epac1 and Piezo2 proteins and genes in the MHb and IPN regions, and the changes in the extracellular levels of glutamate(Glu), aspartic acid(Asp), and glycine(Gly). Compared with the sham group, rats in the SNI group showed significantly reduced analgesic activity, a significant increase in cold pain sensitivity scores, and elevated Glu levels in the MHb and IPN regions. Additionally, the number of Piezo2-positive cells in these regions, as well as the expression levels of Epac1 and Piezo2 proteins and genes, were significantly increased. Compared with the SNI group, after Maxiong Powder administration, the analgesic activity in rats significantly increased, and cold pain sensitivity scores were significantly reduced. Maxiong Powder also significantly decreased the Glu content in the MHb and IPN regions and the Gly content in the MHb region, while significantly increasing the Asp content in both regions. Furthermore, Maxiong Powder significantly reduced the number of Piezo2-positive cells and lowered the protein and gene expression levels of Epac1 and Piezo2 in both brain regions. The central analgesic effect of Maxiong Powder may be related to its inhibition of Glu and Gly release in the extracellular fluid of the MHb and IPN regions, the increase of Asp levels in these regions, and the regulation of the Epac1-Piezo2 pathway through the reduction of Epac1 and Piezo2 protein and gene expression. These results provide partial scientific evidence for the clinical analgesic efficacy of Maxiong Powder and offer new ideas and approaches for the clinical treatment of NPP.
